Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Patients receiving an immune checkpoint inhibitor for a neoplasm face an increased risk for rheumatoid arthritis, an observational study found.

A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Cemiplimab significantly improves DFS in patients with high-risk CSCC post-surgery, reducing recurrence or death risk by 68% compared with placebo. The C-POST trial marks the first immunotherapy ...

Patients who received cemiplimab exhibited significantly reduced risk for recurrence or death compared with those who received placebo. More follow-up is needed to assess OS outcomes. Adjuvant ...

“Precision immunotherapy has been an elusive dream ... the first site selected to test the anti-PD-1 monoclonal antibody cemiplimab in a phase II clinical trial 2 for high-risk cutaneous ...

Immunotherapy enhances your immune system’s ability to target cancer cells. Chemotherapy acts directly on cancer cells to keep them from replicating. Immunotherapy and chemotherapy are two ...

Medicare covers immunotherapy treatment for cancer. Out-of-pocket costs will vary, depending on the Medicare plan a person has and whether or not they have supplemental insurance. If a person has ...